The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Trial of Lixisenatide in Early Parkinson’s Disease
Abstract
BACKGROUND: Lixisenatide, a glucagon-like peptide-1 receptor agonist used for the treatment of diabetes, has shown neuroprotective properties in a mouse model of Parkinson's disease. METHODS: In this phase 2, double-blind, randomized, placebo-controlled trial, we assessed the effect of lixisenatide on the progression of motor disability in persons with Parkinson's disease. Participants in whom Parkinson's disease was diagnosed less than 3 years earlier, who were receiving a stable dose of medications to treat symptoms, and who did not have motor complications were randomly assigned in a 1:1 ratio to daily subcutaneous lixisenatide or placebo for 12 months, followed by a 2-month washout period. The primary end point was the change from baseline in scores on the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III (range, 0 to 132, with higher scores indicating greater motor disability), which was assessed in patients in the on-medication state at 12 months. Secondary end points included other MDS-UPDRS subscores at 6, 12, and 14 months and doses of levodopa equivalent. RESULTS: A total of 156 persons were enrolled, with 78 assigned to each group. MDS-UPDRS part III scores at baseline were approximately 15 in both groups. At 12 months, scores on the MDS-UPDRS part III had changed by -0.04 points (indicating improvement) in the lixisenatide group and 3.04 points (indicating worsening disability) in the placebo group (difference, 3.08; 95% confidence interval, 0.86 to 5.30; P = 0.007). At 14 months, after a 2-month washout period, the mean MDS-UPDRS motor scores in the off-medication state were 17.7 (95% CI, 15.7 to 19.7) with lixisenatide and 20.6 (95% CI, 18.5 to 22.8) with placebo. Other results relative to the secondary end points did not differ substantially between the groups. Nausea occurred in 46% of participants receiving lixisenatide, and vomiting occurred in 13%. CONCLUSIONS: In participants with early Parkinson's disease, lixisenatide therapy resulted in less progression of motor disability than placebo at 12 months in a phase 2 trial but was associated with gastrointestinal side effects. Longer and larger trials are needed to determine the effects and safety of lixisenatide in persons with Parkinson's disease. (Funded by the French Ministry of Health and others; LIXIPARK ClinicalTrials.gov number, NCT03439943.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Three clinical trials consistently describe a slowed decline in motor function when using the short-acting GLP-1 receptor agonists exenatide and lixisenatide in people with Parkinson's disease; 102-104”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [104]
In the citing paper
“The results showed that liraglutide had a modest positive effect on improving motor function and performed well in terms of safety and tolerability, although there were some manageable gastrointestinal side effects.432”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [432]
In the citing paper
“Treatment with exenatide or lixisenatide for 1 year produced a modest but positive effect on Movement Disorder Society–Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) part III scores in people with recently diagnosed Parkinson’s disease (15, 53).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [53]
In the citing paper
“In Parkinson's disease, phase II trials have shown that GLP-1 RAs such as exenatide and lixisenatide improve motor activity compared to placebo,53,54 and liraglutide has shown improvements in non-motor symptoms, mobility, and quality of life.55”
From The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions (2025) · cites this paper as [54]
In the citing paper
“In addition, lixisenatide slowed motor decline in a phase 2 randomized clinical trial in patients with early Parkinson disease.33”
From Neurodegeneration and Stroke After Semaglutide and Tirzepatide in Patients With Diabetes and Obesity (2025) · cites this paper as [33]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment
Nasreddine, Z. S., Phillips, N. A., Bédirian, V., Charbonneau, S., Whitehead, V., Collin, I., Cummings, J. L., & Chertkow, H. (2005) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2005.53221.x · Cited by 25,553
Hughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378
Goetz, C. G., Tilley, B. C., Shaftman, S. R., Stebbins, G. T., Fahn, S., Martinez‐Martin, P., Poewe, W., Sampaio, C., Stern, M. B., Dodel, R., et al. (2008) · Movement Disorders · doi:10.1002/mds.22340 · Cited by 7,536
Self-citationSystematic review of levodopa dose equivalency reporting in Parkinson's disease
Tomlinson, C. L., Stowe, R., Patel, S., Rick, C., Gray, R., & Clarke, C. E. (2010) · Movement Disorders · doi:10.1002/mds.23429 · Cited by 4,219
JENKINSON, C., FITZPATRICK, R., PETO, V., GREENHALL, R., & HYMAN, N. (1997) · Age and Ageing · doi:10.1093/ageing/26.5.353 · Cited by 1,321
Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson’s disease
Yun, S. P., Kam, T.-I., Panicker, N., Kim, S., Oh, Y., Park, J.-S., Kwon, S.-H., Park, Y. J., Karuppagounder, S. S., Park, H., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0051-5 · Cited by 1,123
Athauda, D., Maclagan, K., Skene, S. S., Bajwa-Joseph, M., Letchford, D., Chowdhury, K., Hibbert, S., Budnik, N., Zampedri, L., Dickson, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31585-4 · Cited by 889
Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD)
Defer, G.-L., Widner, H., Mari�, R.-M., R�my, P., Levivier, M., & Conference Participants: Conference Participants: G. L. Defer, M. (. (1999) · Movement Disorders · doi:10.1002/1531-8257(199907)14:4<572::aid-mds1005>3.0.co;2-c · Cited by 865
Exenatide and the treatment of patients with Parkinson's disease
Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Ell, P., Soderlund, T., Whitton, P., Wyse, R., Isaacs, T., Lees, A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68295 · Cited by 529
Self-citationTrial of Prasinezumab in Early-Stage Parkinson’s Disease
Pagano, G., Taylor, K. I., Anzures-Cabrera, J., Marchesi, M., Simuni, T., Marek, K., Postuma, R. B., Pavese, N., Stocchi, F., Azulay, J.-P., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2202867 · Cited by 421
Cited by
Items 201–300 of 368
Tsai, S.-T., Lai, Z.-L., Lu, M., Walther-Antonio, M. R. S., Hsu, Y.-Y., Chao, D., Chen, C.-Y., Vettleson-Trutza, S. A., Kuo, J. S., Yang, C.-C., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-26312-6 · Cited by 2
“Meissner et al.. published striking results of a phase 2, double-blind, randomized, placebo-controlled trial 10 .”
KHAN, A. R., Makhoul, G. W., & Raji, M. A. (2025) · Endocrine Regulations · doi:10.2478/enr-2025-0030 · Cited by 2
“Preclinical studies have suggested that these agents reduce neuroinflammation and oxidative stress, mechanisms implicated in neurodegenerative diseases such as Alzheimer’s and Parkinson’s (Talbot and Wang 2014; Zhang et al. 2019; Meissner et al. 2024; Cummings et al. 2025.”
GLP-1 agonists in neurodegeneration: a multimodal biomarker-guided approach
Santiago, J. A., Gutierrez-Silva, J. C., Hsu, W.-C., Sanchez, K., Almanza, C., Ramos, W., Haq, I. U., & Rundek, T. (2025) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2025.12.001 · Cited by 4
Béchet, S., Leonard, M. V., Ademola, E., Fritz, J. V., & Krüger, R. (2025) · Journal of Neural Transmission · doi:10.1007/s00702-025-03090-z · Cited by 5
The challenges of experimental pharmacology in identifying novel treatments for Parkinson's disease
Teil, M., & Huot, P. (2026) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2025.103164 · Cited by 2
Balamurugan, V., & Sivasankari, K. (2026) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2026033 · Cited by 2
Semaglutide for Alzheimer's disease after evoke and evoke+
Schneider, L. S. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00514-3 · Cited by 3
Raza, H., Nizam, B., Padaniya, A., Farid, M. A., Nabi, A., Hasan, M. Q., Salih, M., Patel, A. H., Inam, N., Rehman, M. E. U., et al. (2026) · Brain and Behavior · doi:10.1002/brb3.71344 · Cited by 2
“All these analyses also did not find any significant effects of treatment, which is consistent with the findings of Mcgarry et al. ( 2024 ); Meissner et al. ( 2024 ), and others who had minimal difference found between the active and placebo groups in functional measures and quality-of-life…”
InfluentialJuthi, S. S., Ansari, P., Ahmed, M. F., Khan, J. T., Seidel, V., Kumar, S., Kumari, R., McKillop, A. M., Abdel‐Wahab, Y. H. A., & Flatt, P. R. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1798309 · Cited by 2
“…studies of dual GLP-1/GIP receptor agonists such as tirzepatide demonstrate synergistic actions, combining GLP-1–mediated anti-inflammatory effects with GIP-driven neurotrophic support, thereby enhancing dopaminergic neuron preservation and improving motor function (Meissner et al., 2024).”
InfluentialPostprandial Hypotension—Methods for the Evaluation and Management
Ishikawa, J., Toba, A., Futami, S., & Harada, K. (2026) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/ggi.70456 · Cited by 2
“Recent studies have shown that exenatide improves off-medication motor scores in PD [57] and that lix-isenatide reduces motor disability progression at 12 months in early PD [58].”
Ali, M., Sharma, A., Paruchuri, A. V., Shahzad, F., Khalid, M. B., Nb, K., Avanaki, M., Nithyanandam, A., Khan, T., & Suresh, V. (2026) · Neurological Sciences · doi:10.1007/s10072-026-08929-1 · Cited by 5
GLP-1 and Parkinson’s Disease: A Comprehensive Review of Biology, Mechanisms and Efficacy
Mezabrovschi, R., Gegg, M. E., & Schapira, A. H. V. (2026) · Cells · doi:10.3390/cells15090804 · Cited by 3
“More recently, a 14-month double-blind Phase II trial in early-stage PD reported a modest but statistically significant improvement in motor outcomes, supporting the hypothesis that earlier intervention may be associated with improved outcomes [168].”
Dahshan, A., Khalil, M. I. M., El-Jaafary, S. I., & Yamani, A. (2026) · Clinical Parkinsonism & Related Disorders · doi:10.1016/j.prdoa.2026.100461 · Cited by 2
“In addition, the effects of GLP-1RAs on gastric emptying may alter levodopa absorption in Parkinson's disease, potentially confounding motor outcomes independent of neuroprotective mechanisms [16,38].”
InfluentialLi, Y., Glotfelty, E. J., Parekh, P., Batsaikhan, B., Luo, W., Jackson, S. N., Harvey, B. K., & Greig, N. H. (2026) · Cells · doi:10.3390/cells15141301 · Cited by 2
“Data on brain uptake in humans is largely lacking, but the GLP-1R peptide agonist exenatide has a reported CSF/plasma concentration ratio of 1–2% [70,71], and has demonstrated both positive actions and a lack of action in human neurodegenerative disorders [70,72–77].”
First phase 3 trial of GLP-1 receptor agonist for neurodegeneration
Kalia, L. V. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00161-8 · Cited by 2
Tu, Y., & Yu, H. (2025) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2024.99 · Cited by 5
Yang, G., Burgess, S., & Schooling, C. M. (2026) · Translational Psychiatry · doi:10.1038/s41398-026-04244-7 · Cited by 3
Parkinson's Disease Detection Using Deep Learning
Rajasekar, V., Sathya, K., Suresh, P., Nitiish, S., Sharan, R., & Devi, K. N. (2024) · International Conference on Data, Computation and Communication (ICDCC) · doi:10.1109/icdcc62744.2024.10961363 · Cited by 2
Singh, M. P., Balasundaram, M. K., & Singh, A. (2025) · Journal of Neurosciences in Rural Practice · doi:10.25259/jnrp_393_2024 · Cited by 3
Gros, P., Marras, C., Wang, X., Chiu, M., Farkouh, M. E., Emdin, A. L., & Bronskill, S. E. (2025) · Movement Disorders · doi:10.1002/mds.30239 · Cited by 2
Yaghmayee, S., Moazzeni, A. S., Jamialahmadi, T., Karav, S., Yaribeygi, H., Kesharwani, P., & Sahebkar, A. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.06.009 · Cited by 2
Negative findings from trials with NLY01 or deferiprone for Parkinson's disease – Author's reply
McGarry, A. J. (2024) · The Lancet Neurology · doi:10.1016/s1474-4422(24)00163-7 · Cited by 2
Mooradian, A. D. (2024) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00685-x · Cited by 1
“…have protective effects on diverse organ systems such as protecting kidney function in people with or without diabetes [88], and the GLP-1 receptor agonist lixisenatide has been found to delay the progression of Parkinson’s disease [89] and possibly reduce the risk of Alzheimer’s disease [90].”
Structural analysis of a micron-sized deposit of Cu0 in an insulin ball from a person with diabetes
Iwaya, K., Nagase, T., Zako, T., Itoh, Y., Yoshiko, T., Arai, H., Nagami, N., Ishikawa, T., & Sugimura, H. (2025) · Communications Medicine · doi:10.1038/s43856-025-00889-5 · Cited by 2
“Indeed, there are common causes and medications for neuroendocrine disease and diabetes 26 – 28 .”
Portha, B., Liu, J., Movassat, J., & Tourrel‐Cuzin, C. (2025) · Cahiers de Nutrition et de Diététique · doi:10.1016/j.cnd.2025.05.006 · Cited by 1
Mechanisms of glucagon-like-peptide 1 in the brain beyond metabolic effects
Kim, K. S., Park, J. S., & Choi, H. J. (2025) · Annals of Pediatric Endocrinology & Metabolism · doi:10.6065/apem.2448320.160 · Cited by 3
“Their effectiveness in addressing inflammation might be the reason for GLP-1RA effects in neurodegenerative diseases [100,101].”
Repurposing medications to prevent psychosis
Cohen, B. M., McPhie, D. L., Sonntag, K., Lopes, C., & Babb, S. M. (2025) · npj Mental Health Research · doi:10.1038/s44184-025-00169-z · Cited by 2
“They may support neurogenesis and neural growth, and connectivity 15,80 – 84 .”
New Oral GLP-1 Receptor Agonists: Gliprons
Kim, C. (2025) · NeuroTrials · doi:10.65321/ntta.2025.002 · Cited by 1
Metabolic and immune dysfunction at the crossroads between type 1 diabetes and neurodegeneration
D’Addio, F., Bucciarelli, L. G., Lunati, M. E., & Fiorina, P. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156471 · Cited by 2
Lee, J., Park, D. G., & Sung, J. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00815 · Cited by 1
“Notably, GLP-1RAs demonstrated beneficial effects in phase 2 clinical trials for PD [4,5].”
Electrochemical biosensors for the detection of neurodegenerative diseases
Erkaya, Ş., Tig, K., Baysal, Ö. D. Y., Eksik, O., Adıgüzel, Z., Beyhan, S., & Aydemir, N. (2026) · Biomedical Microdevices · doi:10.1007/s10544-025-00783-w · Cited by 1
GLP ‐ 1RAs versus metformin and Parkinson's risk in type 2 diabetes
Sun, M., Wang, X., Lu, Z., Yang, Y., Lv, S., Miao, M., Chen, W., Wu, S., & Zhang, J. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70459 · Cited by 1
“13 In a phase 2 randomized, placebo-controlled trial of lixisenatide in early Parkinson's disease, treatment did not show a definitive disease-modifying effect, and longer and larger trials were deemed necessary to clarify neuroprotective potential.”
Therapeutic efficacy of synthetic analogues of gut hormones in a mouse model of Alzheimer’s disease
Denver, P., Duffy, A. M., Kennedy, R. T., Gault, V. A., & McClean, P. L. (2026) · Neuroscience · doi:10.1016/j.neuroscience.2026.01.038 · Cited by 2
Yelleswarapu, N. K., & Sidiropoulos, C. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27062560 · Cited by 1
“Lixisenatide therapy resulted in modest effects in terms of progression of motor disability in early PD [116].”
Chen, Y., Li, J., Delemotte, L., & Mu, Y. (2026) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6c00224 · Cited by 1
Combination Disease‐Modifying Therapy for Neurodegenerative Diseases Using Repurposed Drugs
Shtilbans, A., & Lang, A. E. (2026) · Annals of Neurology · doi:10.1002/ana.78190 · Cited by 1
Stinson, S. E., Shadrin, A. A., Rahman, Z., Rødevand, L. N., Broce, I., Persson, K., Selbæk, G., Stefánsson, H., Haavik, J., Parker, N., et al. (2026) · EBioMedicine · doi:10.1016/j.ebiom.2026.106254 · Cited by 9
The neuro-metabolic epidemic and the CB1R paradox
Vaccaro, F., Malta, G., Rizzo, M., Plescia, F., & Lavanco, G. (2026) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2026.102631 · Cited by 1
Zhang, L., Peng, F., Wanting, Z., Qianqian, J., Zhang, Z., Bai, B., Xue, G., & Hölscher, C. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1825379 · Cited by 1
Elghanam, Y., & Kim, E. (2026) · Archives of Pharmacal Research · doi:10.1007/s12272-026-01615-y · Cited by 3
“…missing outcome data (Gejl et al. 2016; Mullins et al. 2019; Hogg et al. 2022; Edison et al. 2025), deviations from intended interventions (Aviles-Olmos et al. 2013; Meissner et al. 2024; Dei Cas et al. 2024), and baseline imbalances between groups (Aviles-Olmos et al. 2013; Athauda et al. 2017).”
Mendonça, M. F., Interaminense, A. C., Barros, G. S. T. D. R., Rabelo, L. A., de Oliveira, P. G. G., Sales, R. F., Lyra, A. M. V. D. C., & Silva, H. R. D. S. E. [. (2026) · Neurological Sciences · doi:10.1007/s10072-026-09084-3 · Cited by 3
Anderson, B. J., Daele, D. J. V., Claussen, A. D., Tanenbaum, Z. G., & Owen, S. R. (2026) · Annals of Otology Rhinology & Laryngology · doi:10.1177/00034894261450724 · Cited by 1
Parkinson's disease drug therapies in the clinical trial pipeline: 2015–2024
Buff, S., Pilcicka, A., Pitzer, K., Fiske, B. K., Stott, S., & McFarthing, K. (2026) · Journal of Parkinson s Disease · doi:10.1177/1877718x261454154 · Cited by 2
Self-citationAijaz, M., & Ahmad, S. (2026) · Neurology and Clinical Neuroscience · doi:10.1002/ncn3.70131 · Cited by 1
“Multiple phase 2 trials of GLP-1 receptor agonists have been conducted, with exenatide and lixisenatide suggesting improvements in motor symptoms and potential disease-modifying effects; however, the phase 3 trial of exenatide failed to demonstrate efficacy [41, 108–110].”
Damiens, Q., Mille, V., Faure, J., Toussirot, É., Valnet‐Rabier, M., & Béreau, M. (2026) · Journal of Parkinson s Disease · doi:10.1177/1877718x261432743 · Cited by 3
GLP-1 Receptor Agonists in Neurological Disorders: From Mechanisms to Clinical Translation
Li, P., Gao, Y., & (20030), W. L. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s613616 · Cited by 2
Glucagon-like peptide-1 agonists in Parkinson’s disease: a meta-analysis
Abdallah, A. K., Harb, A., Mansour, A., Nasreldin, A., Hamdy, R., Hatem, N., Mosad, N., Hamouda, M., Hamouda, A., & Arumaithurai, K. (2026) · Neurological Sciences · doi:10.1007/s10072-026-09238-3 · Cited by 2
Thome, A. D., Wang, J., Faridar, A., Zhao, W., Saetzler, V., Beers, D. R., & Appel, S. H. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177855 · Cited by 2
Prete, E. D., Vadi, G., Bellini, G., Carlo, D. T. D., Frosini, D., & Ceravolo, R. (2024) · Neurological Sciences · doi:10.1007/s10072-024-07720-4 · Cited by 1
Wang, Q., Liu, F., Wang, X., Zhong, L., Cai, B., & Chen, T. (2024) · Scientific Reports · doi:10.1038/s41598-024-70758-z · Cited by 3
“…being tested include the glucagon-like peptide-1 receptor agonists exenatide and lixisenatide, which are commonly used to treat diabetes 13,14 ; deferiprone for transfusion-dependent thalassemia 15 ; inosine, a urate precursor and potential antioxidant 16 ; the tyrosine kinase inhibitor…”
BackgroundOjaimi, R. E., Cheisson, G., Cosson, E., Ichaï, C., Jacqueminet, S., Catargi, B., Ouattara, A., Tauveron, I., Valensi, P. E., & Benhamou, D. (2024) · Anaesthesia Critical Care & Pain Medicine · doi:10.1016/j.accpm.2024.101468 · Cited by 1
Pedicino, D., & Volpe, M. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf277 · Cited by 1
Ntelis, S., & Wojeck, B. S. (2025) · Current Hypertension Reports · doi:10.1007/s11906-025-01349-0 · Cited by 1
“Lixisenatide, a GLP-1 RA, recently showed promising results in delaying motor symptoms in early Parkinson’s disease [ 48].”
Diabetes drug slows development of Parkinson’s disease
Adam, D. (2024) · Nature · doi:10.1038/d41586-024-00974-0 · Cited by 1
Impact of GLP-1 Receptor Agonists on Intraocular Pressure in Glaucoma: A Case SeriesPreprint
Johnson, C., Terrell, J. A., Blieden, L. S., & Wirostko, B. M. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4861664 · Cited by 1
Hyphae and HealthspanPreprint
Chambers, P. W. (2024) · Qeios · doi:10.32388/yzhinh.2 · Cited by 1
Chabardès, S., Thobois, S., Mitrofanis, J., Beaudoin‐Gobert, M., Anglade, D., Aubert, N., Auboiroux, V., Bleuet, P., Costecalde, T., Schlichting, E. D., et al. (2025) · medRxiv · doi:10.1101/2025.01.23.25320819 · Cited by 4
Semaglutide Ameliorates Neuroinflammation Caused by Enterogenous Pyrogen in APP/PS1 MicePreprint
Yuan, Y., Zhang, J., Zhang, Z., Zhai, Y., Cheng, X., Xue, L., Zhao, F. L., Cao, L. H., & Wang, H. (2025) · Research Square · doi:10.21203/rs.3.rs-6098406/v1 · Cited by 1
van der Zande, H. J. P., Zemer, A., Vrieling, F., Smeehuijzen, L., Attema, B. J., Muallem, H., Jansen, J., van der Linden, A., Prass, S., Wessels, D. W. R., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.27.661006 · Cited by 2
Alimentos infantiles para el periodo lácteo: parte I
Berruezo, G. F. R. (2009) · ANS. Alimentación, nutrición y salud
A GLP-1 Receptor Agonist Looks Promising in Phase 2 Study for Parkinson's Disease
Talan, J. (2024) · Neurology Today · doi:10.1097/01.nt.0001017612.54350.b4
Greener, M. (2024) · Independent Nurse · doi:10.12968/indn.2024.5.10
Contrasting obesity: is something missing here? Comment
Vincenzo, A. D., Vettor, R., & Rossato, M. (2024) · Internal and Emergency Medicine · doi:10.1007/s11739-024-03646-z
Guiniec, M. L., & Borel, A. (2024) · European Journal of Clinical Nutrition · doi:10.1038/s41430-024-01450-8
“Some studies suggest a neuroprotective action, with possible future implications for neuro-degenerative diseases such as Parkinson ’ s and Alzheimer ’ s [7].”
Essai du lixisénatide dans la maladie de Parkinson précoce
Manus, J.-M. (2024) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(24)00241-7
Lüth, T., Caliebe, A., Gabbert, C., Sendel, S., Laabs, B., König, I. R., Klein, C., & Trinh, J. (2024) · medRxiv · doi:10.1101/2024.09.06.24313168
Abdelhay, B., Aksissou, M., Elkhattabi, L., & Fait, S. (2024) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2024.09.010
Thomas, M., Mastitskaya, S., Parker, S., Cookson, R., Holmes, L., Marsh, A., Ramesh, A. V., Rudd, S., Teo, M., & Mortimer, A. M. (2024) · medRxiv · doi:10.1101/2024.12.04.24318321
Movement disorders in 2024: peripheral and outside the box
Mollenhauer, B., & Lin, C. (2024) · The Lancet Neurology · doi:10.1016/s1474-4422(24)00487-3
Vers un traitement neuroprotecteur dans la MPI ? La cible GLP-1
Meissner, W. G. (2025) · Pratique Neurologique - FMC · doi:10.1016/j.praneu.2025.01.009
Self-citationAssociation of waist circumference with all cause mortality in Parkinson’s disease
Suh, J. H., Heo, S., Kim, Y. W., Lee, S. C., & Yoon, S. Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-92624-2 · Cited by 1
Prajapati, J. L., Dhurandhar, Y., Singh, A. K., Gupta, D. K., Baghel, V. S., Kushwaha, U., & Namdeo, K. P. (2025) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2025.2489558
Stratégies médicamenteuses antiparkinsoniennes
Hopes, L., & Frismand, S. (2025) · Elsevier eBooks · doi:10.1016/b978-2-294-78712-6.00016-6
Self-citationFabbri, M., Mariani, L., Corvol, J., Leung, C., & Rascol, O. (2025) · Elsevier eBooks · doi:10.1016/b978-2-294-78712-6.00019-1
Self-citationThomas, M., Mastitskaya, S., Parker, S., Cookson, R., Holmes, L., Marsh, A., Ramesh, A. V., Rudd, S., Teo, M., & Mortimer, A. M. (2025) · medRxiv · doi:10.1101/2025.07.23.25332036 · Cited by 1
Doherty, P., Duty, S., & Williams, G. H. (2026) · Scientific Reports · doi:10.1038/s41598-026-55378-z
Höglinger, G. U. (2025) · DNP – Die Neurologie & Psychiatrie · doi:10.1007/s15202-025-6541-7
“In einer Phase-II-Studie wurde die Wirksamkeit des GLP-1-RA Lixisenatid hinsichtlich des Verlaufs motorischer Defizite bei Parkinsonkranken untersucht [3].”
Rodríguez-González, I. C., Botello-Villagrana, F., Gomez-Villalobos, S. R., Torres-Mancilla, X. M., González‐Cantú, A., González‐González, M., & Martínez-Ramírez, D. (2025) · Revista de Neurología · doi:10.31083/rn38630
“While the present study did not examine GLP-1–based therapies, these results reinforce the idea that metabolic mechanisms—particularly insulin-related pathways—could play a role in shaping PD progression and symptomatology (Meissner et al ., 2024) [43].”
Vascular epilepsy in adulthood: current status and outlook for research and management
Stefan, H., Hammen, T., & Punia, V. (2025) · Clinical Epileptology · doi:10.1007/s10309-025-00782-0
Pessoa‐Gonçalves, Y. M., Flávio‐Reis, V. H. P., Desidério, C. S., de Sousa, M. A. D., Oliveira, C. J. F., Cury, R. G., & Rodrigues, W. F. (2025) · Neurological Sciences · doi:10.1007/s10072-025-08568-y
Park, M., Lee, H. K., Jin, Y., Yoo, S., Kim, S.-W., Park, S., Hong, J., Hong, J. Y., Hong, I., & Baek, M. S. (2025) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2025.108111
Glucagon-Like Peptide-1: The Role of Calcium in Gut-Glucose Axis
Foamkom, A.-I., Abdelhady, H. G., & Razzaque, M. S. (2025) · Advances in experimental medicine and biology · doi:10.1007/978-3-032-04357-3_10 · Cited by 1
Reframing clinical trial results: Neutral versus negative outcomes
Postma, E. M., Hoogsteder, F. T. C., & Bloem, B. R. (2025) · Med · doi:10.1016/j.medj.2025.100890
Li, Q., Shen, Y., Wang, Y., Liu, J., Chen, Z., Luo, W., Chen, Y., Liu, Y., Zhu, X., Xue, S., et al. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1699907
“…medication regimens (dopamine agonists, levodopa, or MAO-B inhibitors, alone or in combination) for at least 3 months prior to enrollment will maintain their medication throughout the 12-week intervention and 1-year follow-up unless clinical indications necessitate adjustments (36).”
Pharmacologic management of diabetes in older adults
Sia, C. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29025-1.00007-2
Bewegungsstörungen und Erkrankungen des Kleinhirns
Franke, C., Storch, A., & Kamm, C. (2025) · Elsevier eBooks · doi:10.1016/b978-3-437-21344-1.00009-9
Pilśniak, J., Węgrzynek‐Gallina, J., Bednarczyk, B., Buczek, A., Pilśniak, A., Chmiela, T., Jarosińska, A., Siuda, J. S., & Holecki, M. T. (2025) · Life · doi:10.3390/life15121893 · Cited by 2
“Another early PD study of lixisenatide by Meissner et al. [51] showed a significant improvement in MDS-UPDRS part III in the experimental group after 12 months of treat-ment.”
InfluentialBarer, Y., Ast, T., Chodick, G., Twig, G., & Giladi, N. (2025) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2025.108171
Glucagon-like peptide-1 receptor agonists to modulate neuroinflammation and neurogenesis
Elvira, R., Tan, E., & Zhou, Z. D. (2025) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-25-01144
“…early-phase trials report improved cognitive/motor scores, such as slow motor deterioration and improved cognitive function in PD by lixisenatide (Meissner Wassilios et al., 2024) and AD by liraglutide (Edison et al., 2021), several Phase II/III programs, including trials of exenatide in AD and…”
Song, T., Xiang, L., Liu, Y., Pan, H., Wu, Y., Liu, Y., Luo, F., Wang, C., Lei, L., Yao, L., et al. (2026) · Journal of Neurology · doi:10.1007/s00415-026-13617-3 · Cited by 2
Contaldi, E., Bonomi, A., Calandrella, D., Sacilotto, G., Zini, M., Sorbo, F. D., Soliveri, P., Zecchinelli, A., Isaias, I. U., & Pezzoli, G. (2026) · Journal of Neurology · doi:10.1007/s00415-025-13598-9
ZEMB, P. A., & Joulia, F. (2026) · SSRN Electronic Journal · doi:10.2139/ssrn.6068352
Khairuddin, T. H., Azwan, N. N., Ruhaizad, N. R. S., Anuar, ‘. N. H., Suhaimi, N. S. F., Nassir, C. M. N. C. M., Ahmed, M. A., Allam, A. H. A. E., Tajudin, H. H. M., & Jaffer, U. (2025) · International Journal of Modern Education · doi:10.35631/ijmoe.728093
Sonu, S. K., Kusuma, Y., Mitchell, P. J., Phan, T. G., Ma, H., & Yan, B. (2026) · Journal of NeuroInterventional Surgery · doi:10.1136/jnis-2026-025184
Exploring Drug Repurposing: Approaches for Mitigating Parkinson's Disease
Talukder, P., Mohanta, S., Hazra, A., Dasgupta, M., Biswas, S., & Hore, S. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898814533126010009
Rissardo, J. P., & Caprara, A. L. F. (2026) · Brain Circulation · doi:10.4103/bc.bc_75_25
Bang, Y., Lee, S., Gal, J., & Choi, H. J. (2026) · Drug Targets and Therapeutics · doi:10.58502/dtt.25.0020
Diabetic signature on Parkinson’s disease: Insights into pathophysiology and therapeutic repurposing
Venugopal, R., Vijayaraghavan, A., Krishnan, S., Puthenveedu, D. K., Surendran, V., & Sachithanandan, S. (2026) · Annals of Movement Disorders · doi:10.4103/aomd.aomd_64_25
Metadata
- Authors
- Meissner, W. G., Remy, P., Giordana, C., Maltête, D., Derkinderen, P., Houéto, J.-L., Anheim, M., Benatru, I., Boraud, T., Brefel-Courbon, C., Carrière, N., Catala, H., Charif, M., Colin, O., Corvol, J.-C., Damier, P., Dellapina, E., Devos, D., Drapier, S., Fabbri, M., Ferrier, V., Foubert-Samier, A., Frismand-Kryloff, S., Geny, C., Georget, A., Germain, C., Grimaldi, S., Hardy, C., Hopes, L., Krystkowiak, P., Laurens, B., Lefaucheur, R., Mariani, L.-L., Marques, A., Marse, C., Ory-Magne, F., Rigalleau, V., Salhi, H., Saubion, A., Stott, S. R. W., Thalamas, C., Thiriez, C., Tir, M., Wyse, R. K., Benard, A., & Rascol, O.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- French Clinical Research Network for Parkinson’s Disease and Movement Disorders (NS-Park/F-CRIN), France
- Université Côte d'Azur (FR)
- Inserm (FR)
- Clinical Investigation Center CIC1436 and Departments of Clinical Pharmacology and Neurosciences, Centre Expert Parkinson, University Hospital of Toulouse, INSERM, University of Toulouse 3, Toulouse, France
- Université de Bordeaux (FR)
- French Clinical Research Infrastructure Network (FR)
- Centre Hospitalier Régional et Universitaire de Nancy (FR)
- Centre Hospitalier Universitaire Amiens-Picardie (FR)
- Centre Hospitalier Universitaire de Bordeaux (FR)
- Cure Parkinson’s, London, UK
- Centre Hospitalier Universitaire de Caen Normandie (FR)
- Service d’Information Médicale, Clinical Epidemiology Unit (USMR), CHU Bordeaux, F-33000 Bordeaux, France
- ORCID
- Meissner, Wassilios G.
- Maltête, David
- Derkinderen, Pascal
- Houéto, Jean-Luc
- Anheim, Mathieu
- Boraud, Thomas
- Carrière, Nicolas
- Colin, Olivier
- Corvol, Jean-Christophe
- Damier, Philippe
- Dellapina, Estelle
- Devos, David
- Drapier, Sophie
- Fabbri, Margherita
- Grimaldi, Stéphane
- Hopes, Lucie
- Laurens, Brice
- Lefaucheur, Romain
- Mariani, Louise-Laure
- Rigalleau, Vincent
- Stott, Simon R. W.
- Thalamas, Claire
- Thiriez, Claire
- Tir, Mélissa
- Wyse, Richard K.
- Rascol, Olivier
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-04-04
- Volume
- 390
- Issue
- 13
- Pages
- 1176-1185
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4393852482
- Cited by
- 369
- References
- 30
- Citations by year
- 2026: 125 · 2025: 160 · 2024: 83
- FWCI
- 97.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Oskar-Bordeaux (Universite de Bordeaux) (submittedVersion)
- Funders
- Cure Parkinson’s
- French Ministry of Health - PHRC-N
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- lixisenatide, Parkinson's disease, GLP-1 receptor agonists, early-stage Parkinson's disease, MDS-UPDRS III, levodopa equivalent daily dose, nausea, neuroprotection, off-medication state, washout period, subcutaneous administration, anti-inflammatory therapy, neurodegeneration, neuroinflammation
- MeSH terms
- Glucagon-Like Peptide-2 Receptor, Motor Disorders, Glucagon-Like Peptide-1 Receptor Agonists, Antiparkinson Agents, Double-Blind Method, Persons with Disabilities, Humans, Injections, Subcutaneous, Parkinson Disease, Peptides, Treatment Outcome, Disease Progression, Neuroprotective Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.